Bioavailability of 2 Different Nevirapine Extended Release Formulations Compared to Viramune® in HIV-1 Infected Subjects

HIV Infections Clinical Trial

Official title:

Steady State Bioavailability of 2 Different Nevirapine Extended Release Formulations Compared to Steady State 400 mg of Viramune® (200 mg BID), in HIV-1 Infected Subjects, an Open Label, Non Randomised, Multidose and Multistage Parallel Group Study. (ERVIR)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02194179
• Other study ID #: 1100.1489
• Status: Completed
• Phase: Phase 1
• First received: July 17, 2014
• Last updated: July 17, 2014
• Start date: December 2006

Study information

• Verified date: July 2014
• Source: Boehringer Ingelheim
• Contact: n/a
• Is FDA regulated: No
• Health authority: Germany: Federal Institute for Drugs and Medical DevicesUnited States: Food and Drug AdministrationFrance: Agence Nationale de Sécurité du Médicament et des produits de santéSwitzerland: Swissmedic
• Study type: Interventional

Clinical Trial Summary

The objective was to establish the pharmacokinetic (PK) profile at steady state of two different nevirapine (NVP) extended release (XR) formulations at 300 mg or 400 mg daily (QD) under fasted and fed conditions in comparison with the commercially available NVP immediate release (IR) tablet at 200 mg BID (400 mg/day).

Recruitment information / eligibility

• Status: Completed
• Enrollment: 92
• Est. primary completion date: May 2007
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years to 60 Years

Eligibility

Inclusion Criteria:

• HIV-1 infected males or females = 18 and = 60 years of age

• Body mass index 18.5 to 29.9 kg/m2, inclusive

• Signed and dated written informed consent prior to admission to the study in accordance with Good Clinical Practice and local legislation

• Treated with a stable Viramune® BID based regimen since at least 12 weeks prior to study entry. If however, the subject's current Viramune® treatment consists of two 200mg tablets once daily (prescribed off label), the subject is allowed to participate if he/she agrees to switch to Viramune® 200mg twice daily, 14 days before the start of Nevirapine Extended Release.

• An HIV-1 viral load of = 50 c/mL at screening

• Acceptable screening laboratory values that indicate adequate baseline organ function with the following exceptions:

• Alanine aminotransferase (ALT) or aspartate aminotransferase (AST)

=2.5 times the upper limit of normal (ULN) (DAIDS Grade 1) or

• Gamma-glutamyl transferase (GGT) <2.5 times ULN (DAIDS Grade 1)

• Willingness to abstain from alcoholic beverages for 24 hours prior to intensive pharmakokinetic sampling days

• Willingness to abstain from ingesting substances which may alter drug plasma levels by interaction with the cytochrome P450 system during the study

• Willingness to abstain from grapefruit and grapefruit juice, Seville oranges and juice, and St John's wort or milk thistle starting 14 days prior to administration of study medication until the end of the study, and

• Karnofsky performance score =70

Exclusion Criteria:

• Current treatment with any PI

• Participation in another trial with an investigational medicine within two months prior to Day 1 of this study

• Serum creatinine levels >1.5 times ULN at screening

• History of acute illness within 60 days prior to Day 1, which would make the subject, in the opinion of the investigator, unsuitable for the trial

• History or evidence of severe illness, malignancy or any other conditions which would make the subjects, in the opinion of the investigator, unsuitable for the trial

• Any evidence of a clinically relevant concomitant disease, including gastrointestinal, hepatic, renal disorders of clinical relevance

• Surgery of the gastrointestinal tract (except appendectomy and herniotomy)

• Diseases of the central nervous system (such as epilepsy) or psychiatric disorders or neurological disorders

• Chronic or relevant acute infections other than HIV-1 (e.g. hepatitis B virus (HBV), hepatitis C virus (HCV) co infection: A chronic or acute HBV infections is defined as: HBs Ag positive. Chronic or acute HCV infection is defined as: HCV Ab positive and 1 confirmed positive viral load measurement preceding study entry)

• Alcohol or substance abuse within 6 months prior to screening or during the study

• Inability to comply with protocol requirements

• Screening laboratory values <DAIDS grade 1

• All fertile males or females, and their respective partner(s) not willing to use two forms of effective contraception. A double-barrier method must be used. A double-barrier method is defined as e.g.: 1) a condom with spermicidal jelly or with a foam suppository; 2) a diaphragm with spermicide; or 3) a male condom and a diaphragm

• Female of child-bearing potential who:

• Has a positive serum pregnancy test at screening,

• Is breastfeeding,

• Is planning to become pregnant, or

• Is not willing to use barrier method protection or require ethinyl estradiol administration

• Any AIDS-defining illness that is unresolved, symptomatic, or not stable on treatment for at least 12 weeks before the screening visit

• HIV-2 infection

Study Design

Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• HIV Infections

Intervention

Drug:
• NVP XR 400 mg (KCR 25%)

• NVP XR 400 mg (KCR 20%)

• NVP XR 300 mg (KCR 25%)

• NVP XR 300 mg (KCR 20%)

Other:
• high-fat breakfast

Drug:
• NVP IR 200 mg (Viramune®)

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Boehringer Ingelheim

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	AUCt,ss (area under the concentration-time curve of the analyte in plasma at steady state over the time dosing interval t)		up to day 22	No
Primary	Cmin,ss (minimum measured concentration of the analyte in plasma at steady state over the time dosing interval t)		up to day 22	No
Primary	Cmax,ss (maximum measured concentration of the analyte in plasma at steady state over the time dosing interval t)		up to day 22	No
Secondary	Cmax,ss / Cmin,ss ratio		up to day 22	No
Secondary	%PTF (percentage peak-trough fluctuation)		up to day 22	No
Secondary	tmax,ss (time from dosing to the maximum concentration of the analyte in plasma at steady state over the time dosing interval t)		up to day 22	No
Secondary	CL/F,ss (apparent clearance of the analyte in the plasma after extravascular administration at steady state)		up to day 22	No
Secondary	Cavg (average measured concentration of the analyte in plasma at steady state)		up to day 22	No
Secondary	Number of patients with adverse events (AEs)		up to day 57	No
Secondary	Number of patients with clinically relevant changes in clinical laboratory tests		Baseline, up to day 37	No
Secondary	Number of patients with abnormal detectable viral load		Baseline, up to day 37	No
Secondary	Number of patients with clinically relevant changes in vital signs (blood pressure, pulse rate)		Baseline, up to day 37	No
Secondary	Number of patients with clinically relevant changes in 12-lead electrocardiogram (ECG)		Baseline, day 23	No
Secondary	Number of patients with clinically relevant changes in physical examination		Baseline, up to day 37	No
Secondary	Assessment of tolerability by the investigator on a 4-point scale		up to day 37	No

External Links

•   Link